Heatwurx (PCSA) Competitors $0.19 -0.01 (-6.75%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.19 0.00 (-0.72%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. MRSN, MDCX, DYAI, IMA, ITRM, BCAB, RNTX, MAAQ, XCUR, and RVPHShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Mersana Therapeutics (MRSN), Medicus Pharma (MDCX), Dyadic International (DYAI), ImageneBio (IMA), Iterum Therapeutics (ITRM), BioAtla (BCAB), Rein Therapeutics (RNTX), Mana Capital Acquisition (MAAQ), Exicure (XCUR), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors Mersana Therapeutics Medicus Pharma Dyadic International ImageneBio Iterum Therapeutics BioAtla Rein Therapeutics Mana Capital Acquisition Exicure Reviva Pharmaceuticals Heatwurx (NASDAQ:PCSA) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Does the media favor PCSA or MRSN? In the previous week, Mersana Therapeutics had 3 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Mersana Therapeutics and 0 mentions for Heatwurx. Mersana Therapeutics' average media sentiment score of 0.50 beat Heatwurx's score of 0.00 indicating that Mersana Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Heatwurx Neutral Mersana Therapeutics Positive Do institutionals and insiders hold more shares of PCSA or MRSN? 91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by insiders. Comparatively, 13.0% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, PCSA or MRSN? Heatwurx has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Is PCSA or MRSN more profitable? Heatwurx has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. Heatwurx's return on equity of -342.36% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% Mersana Therapeutics -212.94%-990.16%-54.85% Do analysts rate PCSA or MRSN? Heatwurx presently has a consensus target price of $1.00, suggesting a potential upside of 417.06%. Mersana Therapeutics has a consensus target price of $56.60, suggesting a potential upside of 680.69%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Heatwurx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Mersana Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, PCSA or MRSN? Heatwurx has higher earnings, but lower revenue than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.08Mersana Therapeutics$40.50M0.89-$69.19M-$14.62-0.50 SummaryMersana Therapeutics beats Heatwurx on 9 of the 15 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.74M$2.53B$5.77B$10.45BDividend YieldN/A55.05%5.61%4.56%P/E Ratio-0.0823.0280.5026.82Price / SalesN/A484.84454.8291.40Price / CashN/A172.2337.6661.43Price / Book0.425.3515.756.39Net Income-$11.85M$32.95M$3.30B$271.80M7 Day Performance2.00%0.90%5.35%3.51%1 Month Performance-6.57%4.71%7.28%9.58%1 Year Performance-85.78%-2.98%80.79%28.53% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx2.9925 of 5 stars$0.19-6.8%$1.00+417.1%-85.8%$9.74MN/A-0.0820Gap DownMRSNMersana Therapeutics4.1073 of 5 stars$7.04+3.2%$56.60+704.0%-86.6%$34.04M$40.50M-0.48150MDCXMedicus Pharma2.2614 of 5 stars$2.09+11.2%$23.50+1,024.4%N/A$33.49MN/A-1.56N/ANews CoverageGap UpDYAIDyadic International2.7786 of 5 stars$0.97+6.1%$6.00+521.7%-14.4%$32.93M$3.42M-5.087News CoverageHigh Trading VolumeIMAImageneBio2.5734 of 5 stars$9.29+16.7%$35.50+282.1%-59.8%$32M$9.16M-1.2170High Trading VolumeITRMIterum Therapeutics2.5224 of 5 stars$0.66-2.6%$9.00+1,263.0%-36.5%$31.99MN/A-0.7810News CoverageShort Interest ↓Gap UpBCABBioAtla0.506 of 5 stars$0.61+13.9%$5.00+718.1%-63.8%$31.50M$11M-0.5660High Trading VolumeRNTXRein Therapeutics0.7036 of 5 stars$1.34+0.8%N/AN/A$31MN/A-0.509MAAQMana Capital AcquisitionN/A$3.71+0.6%N/A+1,326.0%$30.14MN/A0.001Gap UpXCURExicure0.7535 of 5 stars$4.30-9.5%N/A-9.2%$30.01M$500K-1.1150Gap DownRVPHReviva Pharmaceuticals3.1887 of 5 stars$0.45+1.8%$5.20+1,063.3%-79.2%$29.85MN/A-0.695News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Mersana Therapeutics Alternatives Medicus Pharma Alternatives Dyadic International Alternatives ImageneBio Alternatives Iterum Therapeutics Alternatives BioAtla Alternatives Rein Therapeutics Alternatives Mana Capital Acquisition Alternatives Exicure Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCSA Stock Alerts